ANRO Stock Price | Alto Neuroscience, Inc. P/E, Revenue, EPS, & Forecasts

Alto Neuroscience, Inc. • ANRO

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Alto Neuroscience, Inc.

Ticker

ANRO

Trading on

NYSE

ISIN

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Amit Etkin M.D., Ph.D.

Headquarters

650 Castro Street, Mountain View, CA, United States, 94041

Employees

Website

altoneuroscience.com

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.

Metrics

BasicAdvanced

Market cap

$68.5M

P/E ratio

EPS

-$2.50

Dividend Yield

0.00%

Beta

Forward P/E ratio

EBIDTA

$-68.2M

Ex dividend date

Price & volume

Market cap

$68.5M

Average daily volume

0.4M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

Price to book

0.47

Earnings

EPS

-$2.50

EPS estimate (current quarter)

$0.00

EPS estimate (next quarter)

$0.00

EBITDA

$-68.2M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

52-week High

$17.55

52-week Low

$2.44

50-day moving average

$3.58

200-day moving average

$7.84

Short ratio

8.92

Short %

17.69%

Management effectiveness

ROE (TTM)

52.01%

ROA (TTM)

32.36%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

27.1M

Float

19.4M

Insiders %

7.48%

Institutions %

89.38%

Analyst Insights & forecasts

86% Buy

14% Hold

0% Sell

Based on information from 7 analysts.

Average price target

$12.72

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.76

-$0.46

65.22%

Q1 • 24Beat

-$0.60

-$0.67

10.45%

Q2 • 24Beat

-$0.62

-$0.64

3.13%

Q3 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-16.8M

∞%

Q3 • 24

$0M

$-15.2M

∞%

Q4 • 24

NaN%

9.43%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$192M

$26.6M

13.86%

Q3 • 24

$178M

$26.1M

14.69%

Q4 • 24

7.34%

1.78%

6.00%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-11.7M

$-1M

$1.3M

$-12.7M

Q3 • 24

$-13M

$-0.5M

$0M

$-13.5M

Q4 • 24

11.04%

49.65%

96.28%

6.25%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Alto Neuroscience, Inc. share?

Alto Neuroscience, Inc. shares are currently traded for undefined per share.

How many shares does Alto Neuroscience, Inc. have?

Alto Neuroscience, Inc. currently has 27.1M shares.

Does Alto Neuroscience, Inc. pay dividends?

No, Alto Neuroscience, Inc. doesn't pay dividends.

What is Alto Neuroscience, Inc. 52 week high?

Alto Neuroscience, Inc. 52 week high is $17.55.

What is Alto Neuroscience, Inc. 52 week low?

Alto Neuroscience, Inc. 52 week low is $2.44.

What is the 200-day moving average of Alto Neuroscience, Inc.?

Alto Neuroscience, Inc. 200-day moving average is $7.84.

Who is Alto Neuroscience, Inc. CEO?

The CEO of Alto Neuroscience, Inc. is Dr. Amit Etkin M.D., Ph.D..

How many employees Alto Neuroscience, Inc. has?

Alto Neuroscience, Inc. has 0 employees.

What is the market cap of Alto Neuroscience, Inc.?

The market cap of Alto Neuroscience, Inc. is $68.5M.

What is the P/E of Alto Neuroscience, Inc.?

The current P/E of Alto Neuroscience, Inc. is null.

What is the EPS of Alto Neuroscience, Inc.?

The EPS of Alto Neuroscience, Inc. is -$2.50.

What is the PEG Ratio of Alto Neuroscience, Inc.?

The PEG Ratio of Alto Neuroscience, Inc. is null.

What do analysts say about Alto Neuroscience, Inc.?

According to the analysts Alto Neuroscience, Inc. is considered a buy.